Stocks to Watch: Adobe, Amtech Systems, Ocular Therapeutix
By Ben Glickman
Adobe issued fiscal first-quarter and 2024 revenue guidance below analysts estimates. The software maker also said it could face significant costs or penalties related to a Federal Trade Commission investigation into its disclosure and subscription cancellation practices. Shares fall 5.5% to $590 after-hours.
Amtech Systems warned of weaker demand for its products because of a continued downturn in the semiconductor industry. The semiconductor manufacturing equipment maker said it was looking to cut costs, including by reducing its workforce in areas of its business, and had entered a forbearance agreement with a lender. Shares were down 40% to $3.57 after-hours.
Ocular Therapeutix announced a proposed public offering of stock, the proceeds from which it plans to use to fund the development of one of its treatment candidates. The company didn't say how many shares it would sell in the secondary offering. Shares fall 15% to $3.33 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 13, 2023 18:52 ET (23:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization